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-Abstract- 
Background: An increase of leaky vasculature is important for growth and metastasis 
of hepatocellular carcinoma (HCC).  The paracellular permeability-regulating 
proteins in tumor vessels and adjacent sinusoids have not been studied in HCC 
patients. 
Methods: Expression of an endothelial tight junction protein claudin-5 (CL-5) and a 
standard endothelial marker CD34 were immunohistochemically examined in resected 
specimens from 51 HCC cases.  The relationship between hepatitic or fibrotic grade 
and CL-5 expression pattern in sinusoidal endothelial cells (SECs) was evaluated in the 
tumor-adjacent tissues.  Microvessel density (MVD) highlighted by CD34 or CL-5 was 
examined in tumor tissues.   
Results: In the normal liver, a ubiquitous CL-5 expression was seen in SECs, the 
arteries and portal veins but not in the central veins.  Sinusoidal CL-5 expression was 
downregulated according to the increase of hepatitic or fibrotic grade.  Poor 
differentiation and vasculobiliary invasion were significantly associated with a lower 
CL-5-MVD but not CD34-MVD.  By multivariate analysis, vasculobiliary invasion 
and lower CL-5-MVD were independent factors associated with a lower postoperative 
overall survival rate.   
Conclusions: Attenuated CL-5 expression in SECs may be related to SEC dysfunction 
in injured liver.  Downregulated CL-5 expression in tumor vessels may serve as a 
potential marker for poor prognosis in HCC. 
 
Keywords: hepatocellular carcinoma, tight junction, claudin, sinusoid, angiogenesis, 
microvessel density
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-Introduction- 
      Hepatocellular carcinoma (HCC) is a typical hypervascular neoplasm[1].  For 
such a hypervascular solid tumor, growth and metastasis are supposed to be dependent 
on angiogenesis[2].  Tumor microvessel density (MVD), reflecting angiogenesis in 
tumor areas, was reported to be associated with a worse postoperative survival in HCC 
patients[3].  However, another report showed no significant correlation between MVD 
in HCCs and postoperative prognosis[4].  Not only quantity but also character differs 
between normal and tumor angiogenesis, in terms of morphology and hyperpermeable 
state[2].  It is well recognized that tumor-adjacent sinusoidal endothelial cells (SECs) 
in the cirrhotic liver are morphologically different from normal SECs[5]. 
 The tight junction, an important interellular adhesion machinery, serves two 
main functions in cell layers: organization of the paracellular transport of solutes and 
ions maintaining concentration gradients driving transcellular transport; and restriction 
of membrane lipids and proteins to maintain cellular polarity[6].  Tight junctional 
control depends on the claudin (CL) family of tight junction proteins[6].  Among 
them, claudin-5 (CL-5) is important for maintenance of the tight junctional integrity 
between the vascular endothelium[6].  Nitta et al. reported that the blood-brain barrier 
(BBB) is leaky in CL-5-deficient mice, suggesting that CL-5 is crucial for endothelial 
tight junction[7].   
Many investigators have showed abnormal regulation of claudin family 
proteins in cancer tissues[8].  Our previous report showed that CL-1 downregulation 
in HCC cells was correlated with dedifferentiation, portal invasion, and poor 
postoperative survival[9].  However, there has been no report investigating the 
expression status of claudins in tumor vessels and the adjacent SECs.  This study, 
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therefore, aims to elucidate the relationship between: (1) hepatitic or fibrotic activity 
and sinusoidal CL-5 expression; and (2) MVD highlighted by a standard endothelial 
marker CD34[10] (CD34-MVD) or by CL-5 (CL-5-MVD) in HCC tissues and various 
clinicopathological parameters in HCC patients undergoing hepatectomy.     
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-Patients & Methods- 
Patients  
Fifty-one patients who underwent a hepatectomy for HCC in our institute 
between 1994 and 2003 were enrolled in this study.  The patients included 43 men and 
8 women, who ranged in age from 40 to 80 years with a median age of 64 years.  A 
surgical resection of the HCC was done for therapeutic purposes.  Each patient 
provided HCC tissues and nontumorous liver tissues for pathological examination.  
The cause of liver disease was the hepatitis B virus in 16 patients, the hepatitis C virus 
in 32, and cryptogenic in 3.  Informed consent was obtained from all patients.  The 
study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.  
 
Histopathology 
      Surgically removed specimens were fixed with 10% buffered formalin and 
embedded in paraffin, and 4-μm-thick sections were cut and stained with standard 
hematoxylin-eosin. The tumor cell differentiation was assessed according to criteria of  
the Japan Liver Cancer Study Group[11].  For HCCs showing histological diversity of 
tumor differentiation, the predominant pattern was taken into consideration when 
assigning a grade. 
 The specimens were evaluated for inflammation and fibrosis with reference to 
a semiquantitative standardized scoring system[12] by two pathologists in a blind 
fashion.  The histologic grade of inflammation was scored by evaluating inflammatory 
activity as follows: grade 0, mild portal inflammation only, no activity; 1, minimal 
activity and scant piecemeal necrosis; 2, mild activity with piecemeal necrosis; 3, 
moderate activity with obvious periportal necrosis involving most portal triads; and 4, 
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severe activity with bridging necrosis.  The histologic grade of fibrosis was scored as 
follows: grade 0, no fibrosis; 1, portal fibrous expansion; 2, mild to moderate portal 
fibrosis; 3, periportal fibrosis with bridging; and 4, cirrhosis.   
 
Antibodies and immunohistochemistry 
      A mouse monoclonal antibody against CD34 (QBEnd 10; Dako A/S, Glostrup, 
Denmark) and mouse monoclonal antibody against human CL-5 (Zymed, San Francisco, 
CA) were used to perform immunohistochemical staining with ChemMate Envision 
system (Dako A/S, Glostrup, Denmark).    
      After dewaxing and quenching the endogenous peroxidase with H2O2/methanol, 
the sections were processed to retrieve antigens using a microwave method.  In brief, 
the slides were immersed in 10 mM citric acid (pH 7.0) and heated in a microwave oven 
for 40 minutes (500 W output; Iwatani, Tokyo, Japan).  They were then cooled to room 
temperature for 4 hours.  
      The sections were treated with normal serum for 1 hour to reduce background 
staining, then incubated with primary anti-CD34 antibody diluted 1:50 or anti-CL-5 
antibody diluted 1:200 with 1% bovine serum albumin (BSA) / phosphate-buffered 
saline (PBS) in a humidified chamber at room temperature for 8 hours.  They were 
then washed 3 times with cold 10 mM phosphate buffer (pH 7.2).  Biotinated 
anti-mouse immunoglobulin G in ChemMate Envision system was used as the 
secondary antibody.  The binding products were visualized with 3, 
3’-diaminobenzidine tetrahydrochroride solution, and the nuclei were lightly 
counterstained with hematoxylin.  We confirmed the specificity of CD34 and CL-5 
staining by the negative staining in a control study.  Controls were obtained by 
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replacing the first antibody with 1% BSA/PBS or by incubation with isotypic 
non-specific immunoglobulins. 
 
Evaluation of immunostaining  
      In nontumorous tissues, the sinusoidal CL-5 expression pattern was evaluated as 
follows: 1, ubiquitous CL-5 expression; 2, weaker CL-5 expression when compared 
with those in the arteries or portal veins; and 3, no CL-5 expression.  Typical patterns 
are shown in Figure 1A-C. 
In cancer tissues, MVD was assessed under X 200 fold magnification.  When 
HCCs showed histological diversity on tumor differentiation, the expression of CD34 
and CL-5 was assessed in the area of the predominant grade.  Only the vessels 
showing positive staining were selected for counting.  Large vessels with thick 
muscular walls or with a lumen greater than 50 µm in diameter were excluded.  Five 
areas showing the highest density of staining were selected for counting.  Average 
counts were recorded and expressed as the absolute number of vessels per 0.74 mm2 of 
the sections according to another report[3].  In the case of the large pseudoglandular 
type or large trabecular type, a microvessel of about 40 µm was counted as one vessel 
according to the modified method of Tanigawa et al[3].  Both CD34-highlighted 
MVD and CL-5-highlighted MVD were evaluated in the nearly same area using 
sequential sections. 
   
Patients’ follow up and prognosis 
      After the operation, patients were followed up regularly every month.  When 
intrahepatic recurrence was indicated, we performed a repeat hepatectomy for patients 
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with satisfactory liver function, if feasible.  Either transarterial chemoembolization 
(TACE), percutaneous ethanol injection therapy (PEIT), or radiofrequency ablation 
under laparotomy was selected as the treatment for patients excluded from surgical 
indication.  The follow-up period of these patients ranged from 4 to 166 months 
(median 53 months).   
 
Satistical analysis 
      Statistical differences were analyzed using the chi-square test with Fisher’s exact 
test and the unpaired Student’s t-test or analysis of variance (ANOVA) followed by 
Bonferroni’s post hoc test.  Analyses of overall survival and disease-free survival were 
conducted with the Kaplan-Meire method and the differences in survivals between the 
groups were compared using the log-rank test.  Clinicopathological variables as 
potential prognostic determinants were dichotomized and analyzed for their effect on 
overall and disease-free survival.  Based on the results of a univariate analysis, a few 
prognostic factors were assessed by a subsequent multivariate analysis using Cox’s 
proportional hazards model.  Statistical analyses were done using Stat View (version 
5.0, Abacus Concepts, Inc, Berkeley, CA).  A p value < 0.05 was considered 
significant. 
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-Results- 
Pathological features of HCC and underlying liver disease 
Histological examination revealed the underlying disease of the nontumorous 
liver to be cirrhosis or bridging fibrosis in 23 cases and chronic hepatitis in 26 cases, 
while it revealed a normal liver in 2 cases.  According to the hepatitic activity grades, 
two specimens were classified into grade 0, 3 into grade 1, 24 into grade 2, 18 into 
grade 3, and 4 into grade 4.  Regarding to the fibrotic grades, two were classified into 
grade 1, 9 into grade 1, 17 into grade 2, 18 into grade 3, and 5 into grade 4.  The 
indocyanine green (ICG) retention rate 15 min after administration (ICG-R15) was not 
significantly different between patients showing hepatitic activity grade 0-2 and those 
showing grade 3 or 4 (Table 1).  ICG-R15 was significantly higher in patients showing 
fibrotic grade 3 or 4 than in those showing grade 0-2.  
Fourteen HCCs were classfied as well differentiated, 17 as moderately 
differentiated, and 20 as poorly differentiated or undifferentiated． 
 
Expression patterns of claudin-5 and CD34 in nontumorous sinusoidal endothelial 
cells.  The correlation between CL-5 expression pattern in SECs and ICG-R15 
 CL-5 was expressed in large vessels like the arteries and portal veins but not 
in the central veins (Fig. 1A - C).  In the liver without fibrosis and inflammation, CL-5 
was ubiquitously expressed in every SEC (pattern 1 as shown in Fig. 1A).  However, 
sinusoidal CL-5 expression was diminished in livers showing mild to moderate hepatitis 
or fibrosis (pattern 2 as shown in Fig. 1B).  Furthermore, in cirrhotic liver, little CL-5 
expression was seen in SECs (pattern 3 as shown in Fig. 1C).  Increased hepatitic 
activity grade and fibrotic grade significantly correlated with loss of CL-5 expression in 
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SECs (Table 1).  ICG-R15 in patients showing pattern 1, 2, and 3 of SEC CL-5 
expression were 9.7 ± 4.7 %, 16.4 ± 6.8 %, and 20.7 ± 8.5 %, respectively.  ICG-R15 
was significantly higher in patients showing SEC CL-5 expression pattern 3 than in 
those showing grade SEC CL-5 expression pattern 1 (p=0.0008). 
Unlike CL-5, CD34 was expressed in the endothelium of large vessels, such as 
arteries, portal veins and central veins and in the periportal SECs, regardless of hepatitic 
activity grades or fibrotic stages (Fig. 1D-F).  Midzonal and pericentral SECs did not 
express CD34.   
 
Expression of CD34 and CL-5 in tumor vessels  
      Figure 2A shows HE-stained sections of well differentiated HCC tissues.  
CD34 was ubiquitously expressed in tumor vessels in well differentiated HCCs (Fig. 
2B).  CL-5 was ubiquitously expressed in most CD34-positive tumor vessels in well 
differentiated HCCs (Fig. 2C).  Figure 2D shows HE-stained sections of poorly 
differentiated HCC tissues.  CD34-stained tumor vessels were very scarce in poorly 
differentiated HCCs (Fig. 2E).  Of note, in poorly differentiated HCCs, 
CD34-positive tumor vessels did not necessarily show CL-5 staining (Fig. 2F, compare 
with Fig 2E).  Figure 3 shows a typical expression pattern of CD34 (A) and CL-5(B) 
in the portal tumor thrombus derived from a poorly differentiated HCC.  Tumor 
vessels with positive CD34 staining in the portal tumor thrombus frequently lacked 
CL-5 staining. 
 MVD highlighted by CD34 or CL-5 in HCCs was investigated as a quantitative 
approach.  As shown in Figure 4, CL-5-highlighted MVD (CL-5-MVD), but not 
CD34-highlighted MVD (CD34-MVD), negatively correlated with the maximum size 
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of the tumor.  CL-5-MVD well correlated with CD34-MVD. 
The relationship between various pathological parameters and CL-5- or 
CD34-MVDs is shown in Table 2.  CD34-MVD was significantly decreased in poorly 
differentiated HCCs compared to well and moderately differentiated HCCs.  Other 
parameters, such as tumor size and the presence of vasculobiliary invasion or 
microsatellite lesions did not influence CD34-MVD.   
Regarding CL-5-MVD, large HCCs (equal to or larger than 30mm) had a 
significantly lower CL-5-MVD compared with small HCCs (<30mm).  Poorly 
differentiated HCCs showed a significantly lower CL-5-MVD than well and moderately 
differentiated HCCs.  CL-5-MVD was significantly lower in HCCs with vasculobiliary 
invasion than those without vasculobiliary invasion.  There was no significant 
difference in CL-5-MVD between HCCs with and without microsatellite lesions.  
 
Patient overall and disease-free survival 
 Disease-free and overall postoperative survival rates in HCC patients 
undergoing hepatectomy were investigated for various clinicopathological parameters, 
including CD34- or CL-5-MVD.  The cut-off value of CD34- and CL-5- MVD was set 
at 80 and 47 according to the median.  By univariate analysis, poor differentiation, 
multiple nodules, and the presence of vasculobiliary invasion were significantly 
associated with a lower disease-free survival rate (Table 3).  Vasculobiliary invasion, 
microsatellite lesions and lower CL-5-MVD significantly affected overall survival 
(Table 3).  The overall survival rate was higher in HCC patients showing higher 
CD34-MVD (≥80) than those showing lower CD34-MVD (<80), however without any 
significant difference.       
Sakaguchi et al. CL-5 in HCC tumor vessels and surrounding sinusoids, Revised, 
2007/7/4 12   
 In the subsequent multivariate analysis, multiple nodules (Hazard ratio (HR) 
2.915, 95% confidence interval (CI) 1.473-5.747, p=0.0021) and vasculobiliary invasion 
(HR 2.517, 95% CI 1.093-5.795, p=0.0301) were independent predictive factors for 
poor disease-free survival.  Vasculobiliary invasion (HR 6.466, 95% CI 1.978-21.135, 
p=0.0020) and lower CL-5-MVD (HR 2.747, 95% CI 1.071-7.042, p=0.0355) were 
independent factors associated with a lower overall survival rate (Fig. 5). 
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-Discussion-  
  There have been many reports investigating the expression of claudins, major 
tight junction proteins, in various cancer tissues[8, 13-15].  However, investigators 
have focused on the expression in cancer cells.  Our previous report demonstrated that 
the downregulation of CL-1 expression in HCC cells correlates with dedifferentiation, 
portal invasion, and poor prognosis after hepatectomy[9].  Cheung and 
colleagues[16] showed that CL-10 upregulation in HCC tissues is associated with 
recurrence of HCC after hepatectomy, but it remains unclear what kinds of cells are 
responsible for the upregulation.  No information has been available on the expression 
status of claudins in tumor vessels.  Therefore, we focused on tight junction protein 
expression in tumor vessels in HCC tissues as well as in adjacent SECs.  CL-5 
expression was immunohistochemically evaluated because of its specificity in vascular 
endothelial cells[6, 7]. 
Angiogenesis is essential for the development of malignant tumors and favors 
progression and metastasis[2], especially in HCC[1].  However, angiogenesis, 
usually estimated by MVD, does not necessarily correlate with postoperative prognosis 
in HCC patients.  Tanigawa et al. demonstrated that increased CD34-MVD as well as 
dedifferentiation is an independent negative prognostic factor for postoperative 
survival[3].  On the other hand, Sun et al demonstrated that CD34-MVD does not 
correlate with disease-free or overall survival after hepatectomy for HCC[4].  It is 
well recognized that the maximum diameter of HCC is associated with poor 
postoperative survival[4].  El-Assal et al[1]. demonstrated that small HCCs (≤2cm) 
had a significantly lower CD34-MVD than middle-sized HCCs (2-5cm), whereas 
CD34-MVD of large HCCs (>5cm) was lower than that of middle-sized HCC.  
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Therefore, intratumoral CD34-MVD may not be a reliable prognostic factor for HCC 
patients.   
 Tumor vessels have specific characteristics such as a tortuous form, irregular 
shape, and hyperpermeable state[2].  We have speculated that disruption of the 
integrity of interepithelial tight junctions may be one of the causes of hyperpermeability.  
To test this hypothesis, we examined the expression status of CL-5, an important protein 
in epithelial tight junctions[6, 7], in HCC tissues.  Furthermore, SECs change their 
phenotype, so-called “sinusoidal capillarization”, with the development of cirrhosis[5].  
Since we speculate that such phenotypic change affects the status of tight junctions in 
SECs, the CL-5 expression pattern in the tumor-adjacent liver tissues was also evaluated 
in the present study. 
 CD34, a standard epithelial marker[10], is expressed in the periportal SECs as 
well as large vessels such as the arteries, portal veins, and central veins, irrespective of 
hepatitic or fibrotic grade (Fig 1D-F).  These results are identical to the observations of 
Tanigawa and colleagues[3].  Ohmori and associates also reported that CD34 was 
sporadically expressed in the periportal SECs in the hepatitis C-associated chronic 
hepatitic livers, using biopsy specimens[17].  Moreover, they demonstrated that 
higher CD34-positive SEC count was correlated with higher stage of hepatic fibrosis as 
well as HCC development within 5 years of the liver biopsy[17].  Taken together, 
many investigators suggest that CD34 expression in the periportal SECs is a marker for 
sinusoidal capillarization[18].  In our results, CD34 expression was seen in the 
periportal SECs of the normal liver as well.  We speculate that the discrepancy of 
CD34 expression in SECs from periportal to pericentral area may depend on functional 
diversity of SECs.  Further study will be needed. 
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      The study on CL-5 expression in the liver is very limited.  Rahner et al. 
reported that CL-5 was expressed in the large vessel endothelial cells but not in SECs of 
rat livers[19].  In this study, CL-5 is ubiquitously expressed in the arteries and the 
portal veins but not in the central veins irrespective of hepatitic or fibrotic grade (Fig 
1A-C).  In the normal liver without hepatitis and fibrosis, CL-5 was ubiquitously 
expressed in SECs (Fig 1A).  It remains unclear why CL-5 was detected in the human 
SECs in our study.   The difference in species (rat vs human) may be involved in a 
variety of CL-5 expression in vessels of hepatic tissue.  Importantly in the present 
study, CL-5 expression in SECs diminished with the development of hepatitis and 
fibrosis (Fig 1E and F, and Table 1).  Downregulation of CL-5 expression in SECs 
correlated with increased ICG-R15 levels in this study, suggesting the dysfunction of 
hepatic uptake or transportation of substances by hepatocytes[20].  To our knowledge, 
this is the first study to show that selective CL-5 downregulation in SECs well 
correlates with dysfunction of the liver. 
 The relationship between intratumoral MVD and postoperative prognosis is 
controversial[3, 4].  In this study, CD34-MVD did not significantly correlate with 
vasculobiliary invasion or microsatellite lesions, two significant negative prognostic 
factors for postoperative overall survival (Tables 2 and 3).  On the other hand, 
vasculobiliary invasion was significantly associated with lower CL-5-MVD (Tables 2 
and 3).  Furthermore, the multivariate analysis revealed that vasculobiliary invasion 
and lower CL-5-MVD are independent prognostic factors for postoperative survival.  
As shown in Fig. 2 and 3, some tumor vessels showing CD34 staining lacked CL-5 
staining.  This might be associated with the finding that lower CD34-MVD did not 
significantly affect postoperative survival. 
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 CL-5 is crucial for the maintenance of epithelial tight junctions[6].  Nitta et 
al. reported that CL-5-deficient mice showed selective hyperpermeability of the BBB 
for small molecules[7].  Stamatovic et al. demonstrated that monocyte 
chemoattractant protein-1 (MCP-1) increases the permeability of the BBB to fluorescein 
isothiocyanate (FITC)-conjugated albumin, a relatively large molecule, probably 
through a decrease in tight junction proteins such as ZO-1, ZO-2, occludin and 
CL-5[21].  Extravasation of such substances may cause the interstitial fluid 
pressure[2].  Increased interstitial fluid pressure (IFP) is suitable for cancers in terms 
of the following cascade.  Increased IFP causes an imbalance of blood supply, leading 
to hypoxia and acidosis.  Hypoxia, in turn, induces genetic instability and selects for 
more malignant cells with increased metastatic potential[22].  Hypoxia and acidosis 
also compromise the cytotoxic function of immune cells[2].  Taken together, the 
negative correlation between CL-5-MVD and tumor size (Fig. 4) may be the cause as 
well as the effect of the increased IFP. 
 In this study, we did not perform a functional analysis of tumor vessels or SECs 
because of technical difficulties.  Also, it remains unclear why CL-5 expression is 
downregulated in tumor vessels of HCCs showing a poor prognosis and in SECs in 
injured liver.  As mentioned above, MCP-1 may be responsible for CL-5 
downregulation.  First, MCP-1 was verified to decrease CL-5 protein expression and 
increase permeability in brain endothelial cells through the activation of a Rho signaling 
cascade[23].  Second, MCP-1 expression is upregulated in bile duct and 
perisinusoidal cells with the progression of hepatic inflammation[24, 25].  Third, 
HCC cells as well as tumor vessels express MCP-1[26].  Other possible causes of 
CL-5 downregulation are genetic instability and epigenetic abnormality in endothelial 
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cells in tumor tissue.  Hida et al. showed that endothelial cells in tumor tissues 
occasionally have genetic instability such as loss of heterozygosity[27].  Honda et al. 
demonstrated that hypermethylation as well as deacetylation of the CL-4 gene decreases 
CL-4 transcription in ovarian cancer cells[28].  The same transcriptional regulatory 
mechanism may lie behind the regulation of the CL-5 gene.   Further studies will be 
needed to address these issues. 
 In conclusion, attenuated expression of CL-5 in SECs may be related to SEC 
dysfunction in injured liver.  Downregulated CL-5 expression in tumor vessels may 
serve as a useful predictor for poor prognosis in HCC. 
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-Figure Legends- 
Fig 1. 
      Immunostaining of CL-5 (upper panels, A-C) and CD34 (lower panels, D-F) in 
nontumoral liver.  A and D are derived from thin serial sections of the liver showing 
hepatitic activity grade 0 and fibrotic grade 0.  B and E are from liver with grade 1 
hepatitis and grade 1fibrosis.  C and F are from liver showing grade 4 hepatitis and 
grade 4 fibrosis.  The CL-5 expression pattern was evaluated as described in Materials 
& Methods: 1, ubiquitous CL-5 expression in SECs (A); 2, weaker CL-5 expression in 
SECs when compared with those in the arteries or portal veins (B); and 3, no CL-5 
expression in SECs (C). (original magnification, X60).  Arrows and arrowheads 
indicate the portal and central veins, respectively.  Scale bars = 100 μM  
 
Fig 2.  
      Typical staining pattern of CD34 or CL-5 in the tumor vessels of well (A-C) and 
poorly (D-F) differentiated HCCs.  A and D are hematoxylin and eosin-stained 
sections.  CD34 was expressed in tumor vessels of both well (B) and poorly (E) 
differentiated HCCs.  Most of the tumor vessels showing CD34 staining were positive 
for CL-5 in well differentiated HCCs (C).  However, tumor vessels showing CD34 
staining did not necessarily show CL-5 staining (F).  T and N indicate the tumor and 
the adjacent non-tumor tissue, respectively. (original magnification, X40) Scale bars = 
100 μM 
 
Fig 3. 
 Typical CD34 and CL-5 expression in the portal venous tumor thrombus 
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derived from poorly differentiated HCC.  Tumor vessels showing CD34 staining (A) 
frequently lacked CL-5 staining (B) in the portal tumor thrombus. (original 
magnification, X30)  Scale bars = 100 μM 
 
Fig 4. 
      The relationship between tumor size and MVD, highlighted by CD34 (A) and 
CL-5 (B).  The relationship between CD34-MVD and CL-5-MVD is also shown (C). 
 
Fig 5. 
 Overall survival curves after hepatectomy stratified by the existence of 
vasculobiliary invasion (A) and CL-5-MVD values (B).  Existence of vasculobiliary 
invasion and lower CL-5-MVD were significantly associated with a lower overall 
survival rate after hepatectomy. 
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Table 1. 
Influence of hepatitic activity or fibrotic grade on the CL-5 expression pattern in 
SECs and ICG-R15 value according to the CL-5 expression pattern 
 
 CL-5 expression pattern in SECs 
 1 2 3 ICG-R15 (%) 
       
 0, 1, 2 (n) 8 18 3 16.9 ± 7.7 
A grade        * 
 3, 4 (n) 0 7 15 16.9 ± 8.5 
 
 0, 1, 2 (n) 8 18 2 14.9 ± 6.6 
F grade        *    # 
 3, 4 (n) 0 7 16 19.4 ± 8.9 
 
A grade, Hepatitic activity grade; F grade, Fibrotic grade  
ICG-R15, the indocyanine green retention rate 15min after administration 
ICG-R15 data are shown as the mean ± standard deviation 
*:p<0.0001, #:p=0.0438  
 
  
Table 2. 
Relationship between pathological parameters and microvessel densitiy (MVD) highlighted by 
CD34 or CL-5 
 
Factors (n) CD34-MVD  p value CL-5-MVD  p value 
Size 
 <30 (30) 81.8 ± 26.5  0.0562 58.8 ± 27.0 0.0086 
 ≥30 (21) 68.4 ± 20.2   38.3 ± 25.3  
 
Differentiation 
 well / mod (14 / 17) 83.3 ± 26.5 0.0104 65.0 ± 22.7 <0.0001 
 por (20) 65.4 ± 17.5   27.7 ± 18.6 
 
Vasculobiliary invasion 
 Present (19) 70.4 ± 22.1 0.1966 32.4 ± 21.9 0.0002 
 Absent (32) 79.8 ± 26.0   61.0 ± 25.8 
 
Microsatellite lesions 
 Present (12) 78.0 ± 23.0 0.7858 39.8 ± 27.4 0.1365 
 Absent (39) 75.7 ± 25.6   53.6 ± 27.6   
mod, moderately differentiated; por, poorly differentiated  
Data are shown as the mean ± standard deviation 
Table 3. 
Relationship between various clinicopathological parameters and postoperative disease-free or 
overall survival in HCC patients 
 
Factors  (n) 5Y-DFS (%) p value 5Y-OS (%) p value 
Sex 
 male  (42)  21.0  0.7470  58.4 0.4922 
 female  (9)  29.6    63.5 
Differentiation 
 well / mod (14 / 17)  28.4  0.0454  73.3  0.0769 
 por (20)  14.3    33.3  
Tumor number 
 Solitary (30)  32.6  0.0121  61.9  0.2490 
 Multiple (21)  9.5    55.7 
Size  
 < 30 (30)  27.7  0.1820  71.6  0.0848 
 ≥30 (21)  17.1    39.5 
Vasculobiliary invasion 
 Present (19)  11.6  0.0009  18.3 <0.0001 
 Absent (32)  29.2    79.4 
Microsatellite lesion 
 Present (12)  9.4  0.0636  27.9  0.0388 
 Absent (39)  26.0    67.1 
CD34-MVD 
 <80  (25)  26.0  0.2260  43.1 0.0569 
 ≥80  (26)  20.3    73.9 
CL-5-MVD 
 <47 (25)  17.0  0.1005  43.5  0.0368 
 ≥47 (26)  29.0    74.2  
DFS, disease-free survival; OS, overall survival; mod, moderately differentiated; por, poorly 
differentiated; MVD, microvessel density 
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